Cohort studies of survival in systemic lupus erythematosus (SLE) often have been limited by methodologic problems. In studies of inception cohorts of patients followed since 1980, survival at 5 years has exceeded 90%. These estimates are generally higher than survival estimates from earlier studies, suggesting that short-term survival in SLE has improved. There is less evidence to support major improvements over time in survival after 10 years or more of SLE. Infections, atherosclerotic disease, and active systemic lupus erythematosus or organ damage caused by SLE are the main causes of death in patients with SLE, but the proportion of early deaths caused by active SLE has decreased over time. Curr Opin Rheumatol 2001, 13:345-351 Despite improvements in short-term survival, systemic lupus erythematosus (SLE) remains a potentially fatal disease. The most common causes of death include infections, atherosclerotic disease, and active SLE or organ failure resulting from active SLE. Here we review recent studies of mortality and causes of death in SLE, and examine trends in mortality over time and evidence for changes in the principal causes of death.
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Despite improvements in short-term survival, systemic lupus erythematosus (SLE) remains a potentially fatal disease. The most common causes of death include infections, atherosclerotic disease, and active SLE or organ failure resulting from active SLE. Here we review recent studies of mortality and causes of death in SLE, and examine trends in mortality over time and evidence for changes in the principal causes of death.
Cohort studies of survival
Four recent studies have reported survival in cohorts of patients with SLE. Stahl-Hallengren et al. [1••] reported survival in a population-based inception cohort of 81 patients with SLE diagnosed between 1981 and 1991 in a region in southern Sweden. Survival at 5 years was 93%, and at 10 years was 83%. Survival did not differ between those diagnosed in 1981 to 1986 and those diagnosed in 1987 to 1991. The median age at diagnosis was 47 years; the relatively old age of this cohort may have contributed to the finding that 76% of deaths were caused by cardiovascular diseases. Peschken and Esdaile [2••] reported survival in a population-based inception cohort of 179 patients with SLE diagnosed between 1980 and 1996 in Manitoba, Canada. Survival at 5 years, 10 years, and 15 years in a group of white and American Indian patients was approximately 97%, 92%, and 87%, respectively. Mok et al. [3•] reported 5-year survival of 93% in an inception cohort of 182 patients followed from 1992 to 1999 at a tertiary referral center in Hong Kong, China. In a multicenter study from Argentina that did not examine an inception cohort, survival at 5 years and 10 years was 91% and 85%, respectively [4] .
These studies add to a growing list of survival studies in SLE dating from 1955 (Table 1) . When examining these studies for trends in survival over time, it is important to consider the periods over which patients were recruited and person-years of follow-up were accrued, rather than the date of publication. For example, in many instances, publications in the mid-1980s report the survival experience of cohorts followed since the mid-1950s or 1960s, and reflect treatment practices common in those decades. Several additional factors complicate comparisons among reported survival rates. First, most studies report on cohorts followed at particular clinics or referral centers, and differences in patient selection and referral patterns among centers may confound comparisons of estimates of survival among studies. The few population-based studies are much less susceptible to this problem, but differences among population-based cohorts in ethnic or socioeconomic composition, access to care, and local treatment practices may also complicate comparisons of survival estimates. Second, differences among studies in the inclusion or exclusion criteria used to assemble cohorts, or differences in the demographic composition of the cohorts, may affect survival rates. For example, the lower 10-year survival rate in the Swedish population-based inception cohort than in the Canadian population-based inception cohort may be associated with the age of these cohorts, which was on average 10 years higher in the Swedish group [1••,2••]. Third, different studies use different starting points to begin patient follow-up: some use the date of the first SLErelated symptom, some use the date of diagnosis, and some use the date on which American College of Rheumatology classification criteria were first met. If there is a long period between the onset of symptoms and diagnosis, studies that use the date of the first SLE-related symptom as the starting date may report substantially higher survival than studies using the time of diagnosis as the starting date, though there may not have been any difference in patient survival had a similar starting date been used. Fourth, lead time bias may account for an apparent increase in survival over time if patients in more recent studies were diagnosed earlier in the course of their illness as a result of wider availability of more specific serological tests for SLE. Though this factor likely contributed somewhat to increases in survival estimates from the 1950s to the 1980s, it is less likely to have had an impact on survival estimates of cohorts assembled in the 1980s or later. Fifth, studies often fail to report the proportion of patients lost to follow-up at the close of the study. Survival estimates will be spuriously high if a large proportion of unaccounted patients are dead.
Perhaps the most important problem in assessing survival in SLE is that relatively few studies have examined inception cohorts. Studies that do not examine the survival experience of a cohort of patients who each have been followed from the time of diagnosis may underestimate mortality by missing patients who die soon after the onset of SLE, or may overestimate mortality by missing patients with mild disease who are lost to observation soon after diagnosis. Among the 11 studies of ten inception cohorts, survival at 5 years was greater than 90% in all studies of cohorts assembled after 1980 [1••,2••, 3•,32-40] (Table 1) . These estimates generally were higher than those of inception cohorts followed in earlier years. Fewer studies reported data on survival at 10 years, and evidence of an increase in 10-year survival between cohorts assembled before and after 1980 is less striking.
Three groups have directly examined changes in survival over time in cohorts of patients with SLE. Uramoto et al.
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Causes of death
In almost all studies, the three most commonly reported causes of death are active SLE or associated organ failure, infection, and cardiovascular diseases (Table 1) . Examination of trends among these causes of death in patients with SLE is complicated not only by the problems noted, but also by the small number of deaths reported in many studies. The 5-year survival rate of patients with lupus nephritis has improved considerably since the early 1950s, particularly in patients with World Health Organization class IV lupus nephritis. As reviewed by Cameron [51], 5-year survival in these patients has increased from 55% in the 1970s to 90% currently. The improved survival is most likely the result of better immunosuppressive therapy, improvements in dialysis, and renal transplantation.
Infections
Infections remain an important cause of mortality in patients with SLE ( . The diagnosis of tuberculosis may be delayed in patients with SLE because of a frequently atypical radiographic appearance, including miliary disease and patchy consolidations, rather than cavitation and granulomatous changes. The delayed diagnosis may be associated with higher mortality. The most common sites of fatal infections in patients with SLE are the lung, bladder, and joints. Adult respiratory distress syndrome is a common pre mortem event and has a high mortality rate. In a recent study in Korea, the most common cause of adult respiratory distress syndrome in patients with SLE was sepsis caused by gram-negative bacilli [59] . In this study, 68.4% of patients with adult respiratory distress syndrome died, and 32% of all deaths were related to adult respiratory distress syndrome. [61, 62] . Diagnosis of these infections is often delayed, and mortality is high.
Cardiovascular diseases
Cardiovascular disease resulting from accelerated atherosclerosis is increasingly recognized as an important cause of mortality in patients with SLE, and has been the subject of several reviews [63] [64] [65] [66] . A recent study has shown that 13% of patients have atherosclerosis manifesting as angina, myocardial infarction, or peripheral vascular disease [64•]. Autopsy studies reveal that one half of patients had moderate to severe atherosclerosis at the time of death as either an incidental finding or the primary cause of death [27] .
Several studies have searched for risk factors for accelerated atherosclerosis in patients with SLE. Of 200 patients studied at State University of New York-Brooklyn, 15% were found to have coronary artery disease, and significant risk factors included hypertension, postmenopausal status, and older age [65] . Risk factors for coronary artery disease among patients with SLE followed at the University of Pittsburgh included older age, longer disease duration, longer corticosteroid use, hypercholesterolemia, and postmenopausal status [67] . A recent study at the University of Toronto evaluated the influence of hypercholesterolemia on the development of coronary artery disease in patients with SLE [68] . Coronary artery-related events occurred in 3% of patients with normal serum cholesterol levels, 6.4% of those with variable hypercholesterolemia, and 27.8% of those with sustained hypercholesterolemia. Older age, higher cumulative doses of steroids, and lack of prior antimalarial therapy were significant predictors of sustained hypercholesterolemia. 
Conclusions
Further improvement in the survival of patients with SLE will depend on reducing ethnic and socioeconomic disparities in health, improving the balance of the benefits and toxicities of immunosuppressive medications, aggressively treating atherosclerotic risk factors, and understanding better the causes of late mortality. • 70 Petri M: Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus cohort. Lupus 2000, 9:170-175. This study extends the risk factors for coronary artery disease in patients with SLE to elevated homocysteine levels, antiphospholipid antibodies, and renal insufficiency. 
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